Vanucizumab(TD-HT073026) is a research-grade recombinant antibody targetingVascular endothelial growth factor A. Produced in mammalian cells with native-like glycosylation.HighlightsResearch Grade— For PK/PD studies, assay development, and ADA research.Native Glycosylation— Mammalian expression ensures native-like patterns.
Species reactivity
Human
Applications
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host species
Humanized
Isotype
human IgG1 - kappa - lambda with half-IG VL-CH1/VH-CK crossover
Protein A/G purified from cell culture supernatant.
Accession
P15692 & O15123
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Zifibancimig is an anti-VEGFA/ANGPT2 IgG1κ monoclonal antibody.
Caption
Detects Human VEGFA in indirect ELISAs. ### Detects Human ANGPT2 in indirect ELISAs. | SEC-HPLC detection for Research Grade Vanucizumab. | Flow-cytometry using FITC anti-human VEGFA&ANGPT2 antibody. U87 cells were fixed and permeabilized, then stained with an irrelevant antibody (Blue Histogram) or an FITC anti-human VEGFA&ANGPT2 monoclonal antibody (Catalog: HT073026, Yellow Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, cells analysed on a NovoCyte Flow Cytometer.
Note
For research use only. Not suitable for clinical or therapeutic use.